Jupiter Neurosciences (JUNS) Total Equity: History & Chart

Jupiter Neurosciences, Inc.(JUNS)

Biotechnology · Jupiter, FL

$2.86+0.44 (+18.18%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

Jupiter, FL

5 employees

jupiterneurosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christer Rosen

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is ($365,966) with QoQ Growth of +86.85%. Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

JUNS Total Equity

$-365966.00

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $-365966.00.

+90.14% over 10Y

JUNS P/B Ratio

Full P/B Ratio page

P/B Ratio

JUNS P/B Ratio Chart

N/A

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T21:32:38.631Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-04-01.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	($365,966)	+86.85%	N/A
Q1 FY2026Period end 2026-03-31	($2.78M)	(51.95%)	N/A
Q4 FY2025Period end 2025-12-31	($1.83M)	N/A	N/A
Q3 FY2025Period end 2025-09-30	$57,417	(95.72%)	N/A
Q2 FY2025Period end 2025-06-30	$1.34M	(56.27%)	N/A
Q1 FY2025Period end 2025-03-31	$3.06M	(26.54%)	N/A
Q4 FY2024Period end 2024-12-31	$4.17M	N/A	N/A
Q3 FY2024Period end 2024-09-30	($5.75M)	(7.39%)	N/A
Q2 FY2024Period end 2024-06-30	($5.36M)	+11.05%	N/A
Q1 FY2024Period end 2024-03-31	($6.02M)	(3.77%)	N/A
Q4 FY2023Period end 2023-12-31	($5.80M)	N/A	N/A
Q2 FY2022Period end 2022-06-30	($6.20M)	(6.53%)	(66.00%)
Q1 FY2022Period end 2022-03-31	($5.82M)	(12.38%)	N/A
Q4 FY2021Period end 2021-12-31	($5.18M)	(30.10%)	N/A
Q3 FY2021Period end 2021-09-30	($3.98M)	(6.59%)	N/A
Q2 FY2021Period end 2021-06-30	($3.73M)	N/A	N/A
Q4 FY2020Period end 2020-12-31	($3.71M)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.